Firms

Lumira Ventures

Lumira Ventures

lumiraventures.com

Invests in and helps build biotechnology and medical-device companies across North America. The firm supports life sciences businesses at multiple stages, including companies developing medicines for neurological disease, oncology and other serious conditions, and technologies that improve diagnosis and treatment. Its partners work from Toronto, Montréal, Vancouver and Boston. The firm adopted the Lumira name following a management buyout of MDS Capital in 2007.

Founded
—
Type
Venture capital

Funds2

  • Cancer Breakthrough Fund—

    Mission-driven oncology venture fund launched with the Terry Fox Foundation in April 2025 and joined by the Canadian Cancer Society. Announced an oversubscribed first close on May 5, 2026; commitments exceeded the original fundraising target, but an exact closed amount was not disclosed. Combines investment and company-building expertise with philanthropic scientific and clinical networks.

  • Lumira Ventures V, LP—

    Life sciences venture fund launched in 2025 and announced its first close on April 20, 2026. Targets USD200 million final size; the actual first-close amount was not disclosed. Invests in biotechnology and medical technology companies across North America, with disclosed investments including Contraline’s June 2026 Series B.

Team

Beni Rovinski

Lumira Ventures, Managing Director

—— – —
Daniel Hétu

Lumira Ventures, Managing Director

—— – —
Gerry Brunk

Lumira Ventures, Managing Partner

—— – —
—— – —
—— – —
—— – —
—— – —

Operations and support

Bella GiancottaCommunications & Operations Manager
Dahlia AbbottAccounting / Office Manager
Danielle KarakasAnalyst
Isabelle HarrisAssociate
Marc McCoyVenture Clinician
Marco MoyaIT Engineer
Michael LeungController
Suman RaoPrincipal
Theodore WitekSpecial Advisor
Vasco LarcinaCFO

Co-investing

Investments